Infliximab Monotherapy Versus Infliximab and Colchicine Combination Therapy in Patients with Behcet's Disease
Infliximab Monotherapy Versus Infliximab and Colchicine Combination Therapy in Patients with Behcet's Disease
复制标题
DOI：
10.3109/09273948.2012.665124
复制
发表时间：
2012-06-01
影响因子：
3.3
通讯作者：
Mizuki, Nobuhisa
中科院分区：
文献类型：
--
作者：
Takeuchi, Masaki;Asukata, Yuri;Mizuki, Nobuhisa
目的：比较英夫利昔单抗单药治疗与英夫利昔单抗联合秋水仙碱治疗白塞病的疗效。在开始英夫利西单抗治疗后接受其他免疫抑制剂的患者被排除。结果：7例患者接受单药治疗，7例接受联合治疗。单药治疗组的平均眼部发作频率从2.14/6个月降至0.22/6个月，联合治疗组从2.57/6个月降至0.18/6个月。两组之间没有显着差异，观察在0至24 months.Conclusions：英夫利昔单抗和秋水仙碱一起在白塞病治疗的频率和最佳矫正视力的变化。这项研究表明，秋水仙碱管理是没有必要的白塞病患者接受英夫利昔单抗。
Purpose: To compare infliximab monotherapy with infliximab and colchicine combination therapy in Behcet's disease.Methods: Clinical records of 14 Behcet's disease patients who were administered infliximab with or without colchicine were retrospectively reviewed. Patients who were given other immunosuppresants after initiation of infliximab therapy were excluded. The frequency of ocular attacks and best-corrected visual acuity were investigated.Results: Seven patients received monotherapy and 7 received combination therapy. The mean frequency of ocular attacks significantly decreased from 2.14 to 0.22 per 6 months in monotherapy group and from 2.57 to 0.18 per 6 months in combination therapy group. No significant difference was observed between both groups in the frequency of ocular attacks and in changes in best-corrected visual acuity during 0 to 24 months.Conclusions: Infliximab is as efficacious as infliximab and colchicines together in Behcet's disease treatment. This study suggests that colchicine administration is not necessary in Behcet's disease patients receiving infliximab.